O. R. Shirokova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
O. R. Shirokova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Dmitry A. Chichevatov
Penza State University
1 shared publication - E. A. Kolesnikova
Nizhny Novgorod Regional Clinical Oncological Dispensary
1 shared publication - Erkin А. Ashimov
Privolzhsky Research Medical University
1 shared publication - Nikolay Mikhaylovich Kiselev
Nizhny Novgorod Regional Clinical Oncology Center
1 shared publication - Sergey A. Zhurko
Scientific Research Institute – Specialized Cardiac Surgery Clinical Hospital named after Academician B.A. Korolev
1 shared publication - Sergey Andreevich Fedorov
Specialized cardiosurgical clinical hospital named after academician B. A. Korolev
1 shared publication
Latest Publications
- Open Access
- 15 March 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (1) , 21-29
Determination of the Ki-67 threshold value for predicting lymph nodes involvement in patients with gastric cancer
The search for biological markers to assess metastatic involvement of the lymph nodes in gastric cancer is one of the key steps in determining treatment tactics. The role of Ki-67 as a marker of cell proliferation in gastric cancer remains relevant. The aim of our study is to determine the Ki-67 threshold value for predicting the lymph nodes metastases. A retrospective analysis of 154 patients with gastric cancer showed an independent and statistically significant relationship between the depth of tumor invasion T (p = 0.002), the differentiation grade G (p = 0.010), the value of the Ki-67 index (p < 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p >< 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients>< 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p < < 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients >0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients with Ki-67 > 45 %, we found that the median OS was 32 months [HR 2.2; 95 % CI 1.2–3,9; p = 0.005], while it was not reached in the group with Ki-67 < 45 %.A Ki-67 level of ≥ 45 % is the optimal threshold for determining the likelihood of lymph node metastasis in gastric cancer.
- 15 March 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (1) , 21-29
Open AccessDetermination of the Ki-67 threshold value for predicting lymph nodes involvement in patients with gastric cancer
The search for biological markers to assess metastatic involvement of the lymph nodes in gastric cancer is one of the key steps in determining treatment tactics. The role of Ki-67 as a marker of cell proliferation in gastric cancer remains relevant. The aim of our study is to determine the Ki-67 threshold value for predicting the lymph nodes metastases. A retrospective analysis of 154 patients with gastric cancer showed an independent and statistically significant relationship between the depth of tumor invasion T (p = 0.002), the differentiation grade G (p = 0.010), the value of the Ki-67 index (p < 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p >< 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients>< 0.0001) and metastatic involvement of the lymph nodes. Using ROC analysis we found that Ki-67 ≥ 45 % correlates with the optimal level of sensitivity (55.9 %), specificity (84.2 %) and accuracy (73.4 %) of the method AUC 0.738 (p < < 0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients >0.043; 95 % CI 0,654–0,823). When evaluating the overall survival of patients with Ki-67 > 45 %, we found that the median OS was 32 months [HR 2.2; 95 % CI 1.2–3,9; p = 0.005], while it was not reached in the group with Ki-67 < 45 %.A Ki-67 level of ≥ 45 % is the optimal threshold for determining the likelihood of lymph node metastasis in gastric cancer.
- Open Access
- 17 August 2023
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 3,p. 80-86
Surgical Treatment of Aortic Valve Papillary Fibroelastoma in Combination With Coronary Artery Bypass Grafting
Objective: To describe a rare case of surgical treatment of aortic valve papillary fibroelastoma in combination with coronary artery bypass grafting. Clinical case: The patient was hospitalized with a suspected mass on the left coronary cusp of the aortic valve and complained of retrosternal pain that appeared during moderate exertion and brisk walking and went away with rest. The patient history revealed that these clinical manifestations began in February 2022 and were treated by coronary stenting. Since May 2022 the patient noticed symptoms of recurrent angina. Transthoracic echocardiogram dated June 14, 2022 revealed a 13 × 12 mm additional mobile mass on the left coronary cusp. On June 30, 2022 the patient had an open surgery: mass removal, coronary artery bypass grafting of the anterior descending artery, and coronary artery bypass grafting of the circumflex artery. During the aortic valve exploration, the mass was visualized on the left coronary cusp on the side of the left ventricle. The mass was removed by precision marginal excision. Conclusions: To timely examine patients, refer them for surgical treatment, preserve and prolong their life, and improve its quality, clinical practitioners should know clinical manifestations and challenges in screening for aortic valve papillary fibroelastoma.
- 17 August 2023
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 3,p. 80-86
Open AccessSurgical Treatment of Aortic Valve Papillary Fibroelastoma in Combination With Coronary Artery Bypass Grafting
Objective: To describe a rare case of surgical treatment of aortic valve papillary fibroelastoma in combination with coronary artery bypass grafting. Clinical case: The patient was hospitalized with a suspected mass on the left coronary cusp of the aortic valve and complained of retrosternal pain that appeared during moderate exertion and brisk walking and went away with rest. The patient history revealed that these clinical manifestations began in February 2022 and were treated by coronary stenting. Since May 2022 the patient noticed symptoms of recurrent angina. Transthoracic echocardiogram dated June 14, 2022 revealed a 13 × 12 mm additional mobile mass on the left coronary cusp. On June 30, 2022 the patient had an open surgery: mass removal, coronary artery bypass grafting of the anterior descending artery, and coronary artery bypass grafting of the circumflex artery. During the aortic valve exploration, the mass was visualized on the left coronary cusp on the side of the left ventricle. The mass was removed by precision marginal excision. Conclusions: To timely examine patients, refer them for surgical treatment, preserve and prolong their life, and improve its quality, clinical practitioners should know clinical manifestations and challenges in screening for aortic valve papillary fibroelastoma.